KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS G12C • MET amplification • ALK rearrangement • MET exon 14 mutation • MET overexpression • ROS1 rearrangement • MET mutation • KRAS G12 • ALK negative

vebreltinib (APL-101)

Early fibrotic niches establish tumour-permissive microenvironments. (PubMed, Nature)

Disruption of the amphiregulin-EGFR axis prevents early niche formation and abrogates tumour initiation. Conservation of this programme in KRASG12D-inducible human alveolar organoids and early-stage lung adenocarcinoma tissues identifies epithelial-microenvironment communication as a therapeutically actionable vulnerability and suggests that intercepting niche formation may prevent progression to treatment-resistant disease.

1 day ago

Journal

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • EGFR mutation • KRAS G12D • KRAS G12

Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC (ChiCTR2600121611)

P4, N=535, Recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital

2 days ago

New P4 trial • Real-world evidence

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset)

TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • ALK positive • RET fusion • ALK fusion • FGFR mutation • RET mutation • ROS1 fusion • MET mutation • RB1 mutation • NRG1 fusion • KRAS G12 • BRCA mutation

Ivesa (firmonertinib)

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer (ChiCTR2600121351)

P2, N=124, Fudan University Cancer Hospital; Fudan University Cancer Hospital

2 days ago

New P2 trial

KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability)

MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=25, Terminated, Ningbo Newbay Technology Development Co., Ltd | N=120 --> 25 | Trial completion date: Sep 2026 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Sep 2025; Development change

2 days ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12C • KRAS G12

Lumakras (sotorasib)

Cancer-Associated Fibroblast-Derived Sphingosine-1-Phosphate Activates a MALL-SDC4 Axis to Facilitate Perineural Invasion in Pancreatic Cancer. (PubMed, Adv Sci (Weinh))

Disruption of the axis through SPHK1 knockdown in CAFs, genetic perturbation of MALL or SDC4 in cancer cells, or adeno-associated virus-mediated SPHK1 or SDC4 knockdown in KPC (KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx1-Cre) mice significantly reduces PNI and tumor burden. These findings uncover a metabolite-driven MALL-SDC4 program connecting stromal metabolism to neural invasion, and identify promising therapeutic targets for PDAC.

3 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • RHOA (Ras homolog family member A) • SDC4 (Syndecan 4) • PDX1 (Pancreatic And Duodenal Homeobox 1) • SPHK1 (Sphingosine Kinase 1)

KRAS G12D • KRAS G12

Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass. (PubMed, Biochem J)

Together, these effects bypass intrinsic effector selectivity, allowing canonical RAS to co-opt effectors normally associated with other RAS subfamilies and broaden downstream signaling. This framework explains how inherent effector preferences govern normal signaling and how oncogenic mutations override these constraints to expand effector engagement in RAS-driven cancers.

3 days ago

Review • Journal

KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • RAP1A (RAP1A, Member Of RAS Oncogene Family)

KRAS mutation • KRAS G12D • KRAS G12 • NRAS Q61 • NRAS G13 • KRAS Q61

Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC. (PubMed, Cancer Discov)

In a phase I/II clinical trial, patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer treated with the next-generation KRASG12C inhibitor elisrasib showed robust and durable clinical responses. Patients naïve to KRASG12C inhibitors, as well as those refractory to other such drugs, experienced high rates of disease control-98.5% and 83.9%, respectively.

3 days ago

Journal

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12C • KRAS G12

elisrasib (D3S-001)

KontRASt-02: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)

P3, N=95, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Feb 2026 --> Aug 2026

3 days ago

Trial completion date • Trial primary completion date

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12C • KRAS G12

docetaxel • opnurasib (JDQ443)

KRASCENDO 3: A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P3, N=400, Not yet recruiting, Hoffmann-La Roche

3 days ago

New P3 trial

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12C • KRAS G12

Keytruda (pembrolizumab) • Opdivo (nivolumab) • divarasib (RG6330)

KontRASt-06: Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. (clinicaltrials.gov)

P2, N=95, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2026 --> Nov 2027

3 days ago

Trial completion date • IO biomarker

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)

PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12

opnurasib (JDQ443)

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies (clinicaltrials.gov)

P1, N=48, Not yet recruiting, Kumquat Biosciences Inc.

3 days ago

New P1 trial

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12C • KRAS G12 • KRAS G12S